Showing 1621-1630 of 1732 results for "".
- Patient Advocacy Organizations Join Forces to Improve Care for Spinal Muscular Atrophyhttps://practicalneurology.com/news/patient-advocacy-organizations-join-forces-to-improve-care-for-spinal-muscular-atrophy/2468796/Patient advocacy organizations are partnering to obtain real-world evidence to advance research, drug development, and access to therapies for children and adults with spinal muscular atrophy (SMA). Cure SMA and Parent Project Muscular Dystrophy (PPMD) will collaborate to aggregate
- BTK Inhibitor Compared With Ocrelizumab for Primary Progressive MShttps://practicalneurology.com/news/btk-inhibitor-compared-with-ocrelizumab-for-primary-progressive-ms/2485636/Study results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2026 demonstrated that fenebrutinib (Roche, Basel, Switzerland), an investigational oral Bruton tyrosine kinase (BTK) inhibitor, achieved noninferior efficacy compared with Ocrevus (
- Application Submitted to Begin Clinical Development of an Oral Therapy for Agitation in Alzheimer’shttps://practicalneurology.com/news/application-submitted-to-begin-clinical-development-of-an-oral-therapy-for-agitation-in-alzheimers/2485311/Mandara Biopharma (Boulder, CO) has filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) to initiate clinical development of an oral dronabinol formulation for the treatment of agitation associated with Alzheimer disease (AD). The investigational
- Generic Glatiramer Acetate Injection Approved for Multiple Sclerosishttps://practicalneurology.com/news/generic-glatiramer-acetate-injection-approved-for-multiple-sclerosis/2485224/The Food and Drug Administration (FDA) has approved a new formulation of generic glatiramer acetate injection for the treatment of multiple sclerosis (MS), according to an announcement from ScinoPharm Taiwan (Tainan, Taiwan). Glatiramer acetate is an established disease-modifying therapy (DMT) fo
- Driving Patterns May Reveal Early Cognitive Declinehttps://practicalneurology.com/news/driving-patterns-may-reveal-early-cognitive-decline/2484961/Changes in everyday driving behavior may signal early cognitive decline before formal dementia diagnosis, according to a longitudinal study published in Neurology. The study investigators found that passively collected, in-vehicle global positioning system (GPS) data differentiated older
- Subcutaneous Lecanemab for Alzheimer Disease Maintenance Dosing Now Availablehttps://practicalneurology.com/news/subcutaneous-lecanemab-for-alzheimer-disease-maintenance-dosing-now-available/2483895/Leqembi IQLIK (lecanemab-irmb; Eisai, Tokyo, Japan; Biogen, Cambridge, MA), a formulation of lecanemab approved by the Food and Drug Administration (FDA) for subcutaneous injection for maintenance dosing for people with early Alzheimer disease (AD) including those with mild cognitive impairment (
- Peripheral Nerve Stimulation Reduced Chronic Craniofacial Pain in RCThttps://practicalneurology.com/news/peripheral-nerve-stimulation-reduced-chronic-craniofacial-pain-in-rct/2483874/Treatment with the Freedom Peripheral Nerve Stimulation (PNS) System (Curonix, Pompano Beach, FL) significantly reduced chronic craniofacial pain in a multicenter, randomized controlled clinical trial, which provided Level I evidence for the device’s use. Published in Pain Physician, the
- Subcutaneous Lecanemab Approved by FDA for Maintenance Dosing in Alzheimer Diseasehttps://practicalneurology.com/news/subcutaneous-lecanemab-approved-by-fda-for-maintenance-dosing-in-alzheimer-disease/2483177/The Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for a subcutaneous formulation of lecanemab called Leqembi IQLIK (lecanemab-irmb; Eisai, Tokyo, Japan; Biogen, Cambridge, MA) for maintenance dosing for the treatment of people with early Alzheimer disease
- Catherine Chu, MD, to Lead Pediatric Neurology at Kennedy Krieger and Johns Hopkinshttps://practicalneurology.com/news/catherine-chu-md-to-lead-pediatric-neurology-at-kennedy-krieger-and-johns-hopkins/2475483/Catherine Chu, MD, MA, MMSc, has been named Vice President of Child Neurology of the Kennedy Krieger Institute and will also serve as Director of the Division of Pediatric Neurology and the John M. Freeman Pediatric Epilepsy Center at Johns Hopkins Children’s Center. According to a statement rele
- Non-Opioid Drug Significantly Reduced Pain After Surgery, Studies Revealhttps://practicalneurology.com/news/non-opioid-drug-significantly-reduced-pain-after-surgery-studies-reveal/2474650/Treatment with MR-107A-02 (meloxicam; Viatris, Pittsburgh, PA), a novel, oral, fast-acting formulation of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam, was shown to significantly reduce pain and opioid usage vs placebo in top-line results from 2 phase 3 clinical studies. Additionally